Intelligence

#Biology #Drug development #Infectious diseases #MPS technology #Novel therapeutics #Organ-on-a-chip #Toxicology

Hype or hope – microphysiological systems?

Listen to this article on the DDW Podcast: Dr Tomasz Kostrzewski, Director of Biology at CN Bio Innovations, examines MPS in drug discovery as part of a preclinical toolbox.  Drug development remains slow and costly for the pharmaceutical industry, driven by the financial impact of… Read More

#Exclusive Content #Opinion #Trends & Analysis

#Clinical trials #Data #Drug discovery #Life sciences

Clinical trials, the pandemic and technology 

Listen to this article on the DDW Podcast: Chris Sigley, CEO of Arkivum, says the transformation of clinical trials demands a transformed approach to trial data  The pandemic has created manifold challenges for clinical trials, but it has also proved a transformational force. The life sciences… Read More

#Exclusive Content #Trends & Analysis

Pairing the Right Small Molecule Library with Innovative High-Throughput Screening Creates More Therapeutic Opportunity

Finding an encouraging drug lead that selectively engages a target of interest is the result of several critical matches that lead to successful drug discovery programmes, including: Matching a small molecule library with an innovative assay technology Matching a primary screening platform with orthogonal assays to validate hits Matching a… Read More

#Intelligence #Resources

#AI / data analytics / healthtech / informatics #Drug discovery #Technology

Oncology is a major focus for AI drug discovery companies

The application of artificial intelligence (AI) in the drug discovery process is promising to drastically cut down timelines and costs of bringing new therapies to patients. The potential for AI to address these pain points has drawn significant attention from investors and players in the pharmaceutical industry. … Read More

#Market Reports #News #Trends & Analysis

#Digital therapeutics #GlobalData #Pharmaceuticals #Therapeutics

Opportunities in Japan’s neurology digital therapeutics market

Digital therapeutics (DTx) uses digital technology to remotely prevent, treat, or manage a wide range of conditions through data-driven interventions; GlobalData says several opportunities exist in the digital therapeutics market for neurological diseases in Japan.  Shionogi & Co, a partner of Akili Interactive, a prescription digital medicine company of… Read More

#News #Trends & Analysis

#Data #Drug research #Drug therapy

Early therapy gives better outcomes for ulcerative colitis patients, says data  

Galapagos presented data at the United European Gastroenterology Week (UEGW) virtual 2021 congress, which suggests patients with ulcerative colitis (UC) treated with early advanced therapy within the first 18 months post diagnosis showed less residual diarrhoea and required fewer follow-up tests than those who were treated with an advanced therapy later. Read More

#News #Trends & Analysis

#Antibodies #Bispecific therapeutics #Drug development #Drug discovery

Approaching bispecific antibody engineering

Dr Michael Fiebig, Chief Scientific Officer, Absolute Antibody offers insight for those starting with a new bispecific antibody project  who may feel a little daunted by the wealth of formats out there. Over the past 10-plus years, there has been a dramatic rise in the exploitation of bispecific antibodies with… Read More

#Business & Investment #Editor's Choice #Exclusive Content #News #Trends & Analysis

#3D modelling #Liver disease

Ready-to-go spheroids + media for drug discovery

More physiologically and pathologically relevant preclinical human liver models are needed for drug liver liability assessment and liver disease modeling. While Drug-Induced Liver Injury (DILI) remains a major safety concern, several recent high-profile NAFLD/NASH clinical trial failures further highlight this critically unmet need. With the advances in 3D culture, we… Read More

#Intelligence #Resources

#Biotechnology #Collaboration #Data #Technology #Webinar

Webinar reveals how to accelerate your drug discovery program 

This free-to-watch webinar, brought to you by Certara, reviews best practices for using technology to overcome challenges in order to accelerate discovery programs.  Drug discovery research requires understanding complex chemical, biological, logistical, and computational data from a variety of data sources. A key challenge for discovery scientists is efficiently… Read More

#Intelligence #News #Trends & Analysis

#Cell sequencing #Genetics / genomics #Multi-omics

Single-cell Sequencing 101: DNA & Multi-omics for Precision Medicine

Cancer is a complex disease that continuously evolves in response to environmental pressures. The dynamism and heterogeneity of tumours have significant clinical implications. In this eBook, we review how single-cell DNA sequencing and multi-omics are used to dissect clonal architecture, providing valuable insights for clinical strategies, disease modelling, and the… Read More

#DDW eBooks #Intelligence

#Biopharma #Biotechnology #Collaboration #Life sciences #Technology

Why quantum computing in drug discovery needs to improve  

The Pistoia Alliance has released new results from a survey of 260 attendees from life science companies across the globe, finding that almost half classify their understanding of quantum computing (QC) technology at the beginner level (48%) only. This is followed by intermediate (29%), advanced (13%), and expert at… Read More

#News #Trends & Analysis

#Biopharmaceuticals #Covid-19 #GlobalData

Covid-19 shapes Indian pharma deals landscape

India has a rapidly growing pharmaceutical market that, being the third largest pharmaceutical industry in the world by volume, holds a prominent place in global health. Over the last decade, the Indian pharmaceutical market has seen increasing domestic and foreign investment. While the overall number of deals fluctuated only… Read More

#Covid-19 #News #Trends & Analysis